Cargando…
Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer
Taxol is a widely used chemotherapy drug used clinically for ovarian cancer, although the response to Taxol among individuals varies due to the heterogeneity among ovarian cancer patients. In this work, we analyzed differences in the prognostic effect of gene expression and Taxol usage in the Cancer...
Autores principales: | Hou, Shunyu, Dai, Jianrong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832203/ https://www.ncbi.nlm.nih.gov/pubmed/29494610 http://dx.doi.org/10.1371/journal.pone.0192812 |
Ejemplares similares
-
High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer
por: Shen, Yuqing, et al.
Publicado: (2022) -
Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
por: Zhang, Jing, et al.
Publicado: (2021) -
LncRNA SNHG20 predicts a poor prognosis and promotes cell progression in epithelial ovarian cancer
por: Wang, Dandan, et al.
Publicado: (2019) -
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
por: Zhou, Ming, et al.
Publicado: (2010) -
RASSF1A and the Taxol Response in Ovarian Cancer
por: Kassler, Susannah, et al.
Publicado: (2012)